Gist Drugs Not So Dear

''Huge cost of GIST patients spurs alarm'', (BP, Dec 1). It is reported that the treatment costs of gastrointestinal stromal tumour (Gist) have put an enormous burden on the government. Novartis (Thailand), as a manufacturer of cancer drugs, would like to inform that the company is deeply concerned about patient access to medicines.

Consequently, various programmes have been initiated to enhance both affordability and access to medicines and treatments. The International Patient Assistance Programme (GIPAP) was launched...